Redcare Pharmacy Shares: A Fragile Recovery Emerges

Redcare Pharmacy's stock sees a technical rebound as analysts highlight potential benefits from Germany's GKV reforms, though profitability challenges persist.

Positive analyst commentary regarding Germany's healthcare reforms is providing a much-needed lift for Redcare Pharmacy. The stock is attempting a comeback following severe declines over recent months. Analysts at Bankhaus Metzler point to specific advantages for the e-pharmacy sector within the proposed legislative changes, offering the share price at least short-term support.

Profitability Lags Behind Ambitious Growth Targets

Operationally, the company is focusing on its PoPP module for electronic prescriptions, aimed at modernizing the digital infrastructure in German healthcare. Its core growth engine is the Rx segment, covering prescription medications. Management has set a target for Rx revenue to exceed €670 million by 2026. Overall sales are projected to grow between 13% and 15%, with the Non-Rx business expected to increase by 8% to 10%.

This expansion comes at a cost. The last fiscal year concluded with a net loss of €37.7 million. An adjusted EBITDA margin target of at least 2.5% underscores that sustainable profitability remains a future goal. Company leadership states it aims to reach breakeven within the next three financial years. A 13.7% insider ownership stake is noted as aligning the interests of management with those of shareholders.

Technical Rebound Faces Long-Term Hurdles

Recent trading activity highlights the stock's volatility. During a single session this Tuesday, the share price swung approximately 9.8%, moving between €35.76 and €39.26. While short-term moving averages have turned upward and analysts note a buy signal originating from the low on March 27, the longer-term trend remains under pressure. A significant gap of about 47% still exists to the 200-day moving average.

The recovery over the past week is evident, yet the fundamental picture continues to present challenges. Whether the statutory health insurance (GKV) reforms will deliver the anticipated boost will become clearer, at the latest, when the company reports its half-year figures.